Introduction
============

There is a consensus in worldwide recommendations that prescription and non-prescription (over-the-counter, OTC) non-steroidal anti-inflammatory drugs (NSAIDs) should be taken with food or with milk, and that this advice applies also to aspirin, and perhaps to paracetamol. For example, the NICE Clinical Knowledge Summary on NSAIDs advises 'Avoiding taking the NSAID on an empty stomach' and to 'Take aspirin after food (to reduce the risk of gastrointestinal adverse effects)', though it does not give this advice for paracetamol \[[@b1]\]. The UK National Health Service NHS Choices website advises that 'There are no known interactions between NSAIDs and food. Ideally, take NSAIDs after eating and avoid taking them on an empty stomach. This will help minimize the risk of the medicine upsetting your stomach' \[[@b2]\]. German guidelines for family physicians advise that in elderly patients NSAIDs should be taken with food and never on an empty stomach \[[@b3]\]. A consumer\'s guide on arthritis medications endorsed by the Canadian Rheumatology Association suggests that 'Taking your NSAIDs with food may help to reduce stomach upset' \[[@b4]\]. A number of Australian and New Zealand sources echo this general advice, and it appears to be almost universal advice, whatever the circumstance.

The theoretical rationale for taking analgesics with food is clearly to reduce or prevent adverse events. It is unclear whether this means common but mild and reversible adverse events like dyspepsia, or rare but serious adverse events like upper or lower gastrointestinal bleeding. The evidence that taking oral analgesics with food actually accomplishes this desired effect is non-existent. In single dose studies, only aspirin of the commonly used non-opioid analgesics is associated with any increased adverse event reporting over placebo (number needed to harm 44, 95% CI 23, 345) \[[@b5]\]. Rainsford & Bjarnason found no evidence of benefit from taking NSAIDs with food \[[@b6]\]. They suggested that it would be more appropriate to take OTC NSAIDs on an empty stomach because rapid onset of action is beneficial.

More rapid absorption of ibuprofen produces earlier and higher maximum plasma concentrations, producing earlier onset of analgesia combined with better overall and longer lasting analgesia in dental pain models \[[@b7]--[@b9]\]. The effect of fast acting formulations was pronounced, with 200 mg of a fast acting formulation producing the same or better analgesia as 400 mg ibuprofen acid, and with a reduced requirement for additional analgesic use \[[@b8]\].

An understanding of the effects of food on the pharmacokinetics of analgesics has therefore become a priority, particularly its effect on occasional use of OTC drugs. We have therefore conducted a systematic review of studies reporting kinetic results of oral analgesics in the fasted and fed states in humans. We considered any formulation where the drug was immediately available for absorption following ingestion, but excluded those specifically formulated for delayed or controlled release.

Methods
=======

There is no published protocol for this review. Two authors independently carried out searches for potentially relevant studies, assessed studies for inclusion and extracted data using a piloted spreadsheet. Any disagreements were settled by discussion with a third author.

We used a number of methods to search for comparisons of oral analgesics in the fed and fasted states to 31 October 2014. We searched PubMed using a series of free text terms: 'fed AND fasted AND analgesic', and 'fed AND fasted AND drug name', using 'food', 'meal' or 'milk' as alternatives to fed. We also examined reviews for aspirin, paracetamol, and individual NSAIDs where they mentioned pharmacokinetic results, and the reference lists of any retrieved studies. For each identified study we used the 'related citations' function of PubMed to identify reports citing the trial in case the citing reference was also a study reporting on oral analgesics used in the fed and fasted state. Finally, we entered each included trial into Google Scholar and used the citations function to identify reports that cited the trials. Methods like this have been used with good effect to identify non-randomized studies where electronic searching is insensitive \[[@b10],[@b11]\]. We also searched <http://Clinicaltrials.gov> to identify completed or ongoing studies.

To be included, studies were required to have data on kinetic parameters in the fasted and fed state for single doses of aspirin, dipyrone, paracetamol, or any NSAID, or for a principal metabolite in blood following oral administration in humans. There was no restriction by date or language of publication. We accepted any definition of fed, meal or milk. We accepted any formulation other than delayed release formulations. Fast-acting formulations of ibuprofen were analyzed separately from ibuprofen acid, and diclofenac potassium separately from diclofenac sodium.

From each study we noted the study design (whether it was a randomized, crossover design, for example), the number and demographics of the individuals involved in the testing, the duration of fasting, the components of the meals used, the time of drug administration in relation to the meal, and the dose and formulation of the analgesic drug. The kinetic parameters noted were bioavailability (using the longest duration provided), the maximum plasma concentration (*C*~max~) and the time at which *C*~max~ occurred (*t*~max~).

No statistical analyses were planned. Drug concentrations were converted to mg l^--1^ and area under the plasma concentration--time curve (AUC) to mg l^--1^ h. We calculated a mean *t*~max~ for individual drugs weighted by the number of participants in each study. For *C*~max~ we calculated a dose-related mean, weighted by the number of participants in each study, with units of mg l^--1^ mg^--1^ dose. All calculations were carried out by one author and checked by another.

We wanted to compare bioavailability (AUC), *t*~max~ and *C*~max~ in the fed and fasted state.

Results
=======

Studies identified
------------------

Searches identified 63 publications which were obtained and read. Twenty-five were excluded because they collected urine samples only, were reviews without relevant data, investigated delayed release preparations, had no fasting or fed results, or were duplicate publications (Figure[1](#fig01){ref-type="fig"}). Six potentially relevant studies identified in <http://Clinicaltrials.gov> did not provide any results and could not be used (Supplementary Table [1](#SD1){ref-type="supplementary-material"}). We included 38 publications \[[@b12]--[@b49]\] with 656 unique individuals, reporting 46 fed/fasted comparisons involving 874 participants in the comparisons. Papers were published between 1972 and 2012. Because of the crossover nature of many of the studies, the number in the comparisons is more than the number of individuals. Included studies measured the pharmacokinetics of aspirin, dipyrone, paracetamol and 16 different NSAIDs. Fast acting formulations were represented by diclofenac potassium (four studies, the only diclofenac formulation with data), ibuprofen lysine (two studies), naproxen sodium (one study) and paracetamol with bicarbonate (one study).
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###### 

Mean results by drug, weighted by number of participants in pooled analyses

                                                       Number of   Mean *t*~max~ (h) (weighted by *n*)          Mean *C*~max~ (mg l^--1^ mg^--1^ dose ) (weighted by *n*)                           
  ---------------------------------------------------- ----------- ------------------------------------- ------ ----------------------------------------------------------- ----- -------- -------- -----
  **Aspirin (as salicylic acid)**                      3           30                                    1.74   2.65                                                        152   0.093    0.079    85
  **Bromfenac**                                        1           68                                    0.80   2.40                                                        300   0.078    0.022    28
  **Celecoxib**                                        2           51                                    2.72   3.19                                                        117   0.0041   0.0065   159
  **Dexketoprofen trometamol**                         1           21                                    0.63   1.50                                                        238   0.095    0.053    56
  **Diclofenac potassium**                             4           115                                   0.52   1.45                                                        280   0.041    0.022    54
  **Diclofenac sodium**                                3           22                                    1.83   5.12                                                        280   0.025    0.011    44
  **Diflunisal**                                       1           12                                    2.42   3.10                                                        128   0.144    0.120    83
  **Dipyrone (as methylaminoantipyrine)**              1           18                                    1.50   1.90                                                        127   0.010    0.0097   97
  **Etoricoxib**                                       1           12                                    1.00   3.00                                                        300   0.020    0.013    65
  **Ibuprofen acid**                                   6           109                                   1.34   1.96                                                        147   0.076    0.059    78
  **Ibuprofen fast-acting**                            2           43                                    0.71   1.44                                                        203   0.096    0.070    73
  **Indomethacin**                                     3           86                                    1.60   2.95                                                        184   0.065    0.030    46
  **Ketoprofen**                                       2           24                                    1.89   4.76                                                        252   0.153    0.094    61
  **Meloxicam**                                        2           22                                    9.30   7.10                                                        76    0.059    0.068    115
  **Nabumetone (as 6-methoxy-2-naphthlacetic acid)**   1           12                                    3.00   4.00                                                        133   0.023    0.036    157
  **Naproxen**                                         2           24                                    1.90   1.93                                                        102   0.146    0.136    93
  **Naproxen sodium**                                  1           24                                    1.30   3.20                                                        246   0.291    0.229    79
  **Paracetamol**                                      4           77                                    1.58   2.08                                                        132   0.019    0.011    58
  **Paracetamol + bicarbonate**                        1           28                                    0.42   0.75                                                        179   0.024    0.013    54
  **Surprofen**                                        1           24                                    0.92   1.56                                                        170   0.095    0.042    44
  **Tenidap**                                          1           21                                    2.90   4.40                                                        152   0.150    0.153    102
  **Tenoxicam**                                        2           18                                    1.63   5.23                                                        320   0.143    0.118    83
  **Timegadine**                                       1           10                                    3.00   2.40                                                        80    0.0013   0.0028   215

Details of the comparisons are given in Supplementary [Table 2](#SD2){ref-type="supplementary-material"}. Of the 46 comparisons, 33 had a randomized crossover design, 12 had a crossover design but did not mention randomization and one was opportunistic. Study participants were predominantly healthy volunteers generally aged 18--50 years (20 comparisons were male only, 22 were mixed male and female), three studies were in adult patients (post-operative, inpatients, sciatica), and one was in children with cancer. The duration of fasting was typically overnight, usually with a minimum of 10 h before ingesting the test medication. Fasting patients were sometimes given a light meal about 4 h after ingestion. Analgesics were taken with these meals or a few minutes after the meal.

The types of meal were variously described (Supplementary [Table 2](#SD2){ref-type="supplementary-material"}). Twenty-eight comparisons gave details of the meals for volunteers in the fed part of the studies. These typically consisted of tea or coffee, bread or toast with jam, and often with cheese, eggs or bacon. Other meals were described only as standardized, without details (12), as high fat (4), or had some other description (2).

Drug analysis was for the parent compound except for:

-   aspirin, for which salicylic acid concentrations were also reported, and used;

-   dipyrone, where methylaminoantipyrine, the first metabolite of dipyrone which is enzymatically hydrolyzed in the intestine was measured;

-   nabumetone, where 6-methoxy-2-naphthlacetic acid was measured.

Effects of food on bioavailability
----------------------------------

There was no difference in bioavailability between fasting and fed states as measured by the area under the concentration--time curve (Figure[2](#fig02){ref-type="fig"}).
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Effects of food on *t*~max~
---------------------------

Food typically delayed absorption for all drugs with a fasting *t*~max~ of under 4 h (Figure[3](#fig03){ref-type="fig"}, Table [1](#tbl1){ref-type="table"}). The degree of delay varied between drugs, from little or no delay in absorption for celecoxib, diflunisal, dipyrone, meloxicam and timegadine, to an increase of fed *t*~max~ over fasted *t*~max~ of 250% or more for bromfenac, diclofenac, etoricoxib, ketoprofen and tenoxicam. Ibuprofen, paracetamol and naproxen were intermediate between these extremes (Table [1](#tbl1){ref-type="table"}).

![*t*~max~ in fed and fasted state for individual drugs. The inset scale indicates the number of participants in each comparison. Blue symbols are fast-acting formulations of diclofenac potassium, ibuprofen lysine, naproxen sodium and paracetamol plus bicarbonate](bcp0080-0381-f3){#fig03}

Effects of food on *C*~max~
---------------------------

Food reduced the *C*~max~ for all drugs with a fasting *t*~max~ of under 2 h (Table [1](#tbl1){ref-type="table"}). The greatest degree of reduction in *C*~max~ was in analgesics with the shortest fasting *t*~max~, with reductions by about 50% or more for bromfenac, dexketoprofen, diclofenac, indomethacin, paracetamol and surprofen. For celecoxib, nabumetone and timegadine *C*~max~ increased in the fed state, while meloxicam was unaffected.

Discussion
==========

The results of the review are clear. Taking analgesics with food does not affect the overall bioavailability, but for many drugs food substantially prolongs absorption and *t*~max~, while substantially reducing *C*~max~. This is particularly the case for those drugs whose fasting *t*~max~ is below 2 h, which includes analgesics typically available without prescription in many parts of the world, namely aspirin, diclofenac potassium, ibuprofen (as acid and salt) and paracetamol (Figure[4](#fig04){ref-type="fig"}). Naproxen is affected to a much lesser extent.
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The strength of these findings is that the systematic review covered all simple analgesics and NSAIDs, using a search strategy likely to be comprehensive, and which was unrestricted by date or language of publication. Included studies covered a 40 year period from 1972 to 2012. The effects of food on delayed *t*~max~ appeared to be similar in all the drugs examined with a fasting *t*~max~ of 4 h or less. The effects of food on reduced *C*~max~ appeared to be similar in all the drugs examined with a fasting *t*~max~ of less than 2 h. Results were not compromised by the inclusion of delayed or controlled formulations specifically designed to delay absorption.

There are several potential weaknesses. This review covers only a part of the potentially available data, since many bioavailability studies have been performed for regulatory or other purposes, but not published. We are aware that this may be the case from discussions with pharmaceutical companies. Effects of food are often explored to demonstrate bioavailability equivalence following small changes in formulation. This review shows that bioavailability was unaffected by food (Figure[2](#fig02){ref-type="fig"}), and the results of such studies would therefore have been seen as unremarkable and not worthy of publication. Effects on *C*~max~ and *t*~max~ would probably have been overlooked as having no importance. Recent research has shown that *C*~max~ and *t*~max~ are more important than bioavailability, and this study may provoke companies with unpublished studies to revisit them, with a view to confirming the results presented here. We do not consider lack of publication of the reports to be a form of publication bias, since there were no grounds for bias at the time.

Other weaknesses include the small size of many of the individual studies, so some imprecision in the estimates of the magnitude of food effects is therefore likely. There were also insufficient details to determine whether the type of meal had any major consequences for any particular drug, or for drugs in general, and to explore links between physicochemical properties of individual drugs, type of meal and the effects of food. Finally, these data, while relevant to occasional use of analgesics, for headache, for example, cannot necessarily be extrapolated to long term repeat dosing.

The implications of the results are significant, and stem from the increasing understanding of the importance of early, high, plasma drug concentrations for pain relief, particularly in the treatment of acute pain. An analysis of a randomized trial in acute pain demonstrated a direct link between the concentration of ibuprofen and the absence of patients with moderate or severe pain at 1 h after dosing \[[@b7]\]. There was also a direct link between dose, plasma ibuprofen concentration and the changes in Western Ontario and McMaster Universities Osteoarthritis Index and visual analogue scale pain scores between baseline and after 7 days of treatment in osteoarthritis \[[@b50],[@b51]\], with a weak correlation in rheumatoid arthritis \[[@b52]\].

Moreover, two recent patient level analyses of data from different acute pain studies have demonstrated that speed of onset of analgesia is an important determinant of good and possibly long lasting pain relief \[[@b8],[@b9]\]. For fast-acting ibuprofen formulations with a median *t*~max~ of 30--40 min, 200 mg provided the same pain relief after third molar extraction (number needed to treat \[NNT\] for at least 50% maximum pain relief over 6 h 2.9, 95% confidence interval (CI) 2.3, 4.1) as 400 mg ibuprofen acid with a median *t*~max~ of 100 min (NNT 2.7, 95% CI 2.5, 3.1) in a Cochrane review \[[@b53]\] and in an updated analysis \[[@b8]\]. Poor analgesia leads to more frequent recourse to additional analgesic consumption \[[@b8],[@b9]\].

At least for ibuprofen, where we have most information, early, high plasma concentrations produce better analgesia in acute pain, and result in reduced need for remedication (Figure[5](#fig05){ref-type="fig"}). There is no obvious reason why this should not be the case for other analgesics. If taking analgesics with food delays absorption and reduces peak plasma concentrations, poorer analgesia is likely to result. This indeed is what happened in the only test of taking food with analgesics we could find, with bromfenac \[[@b22]\], though the effects of food on paracetamol and naproxen were minimal. The impact on efficacy of taking analgesics with food is largely unexplored in acute and chronic pain, and this makes the case for new studies examining the effects of food on analgesic effects, as well as pharmacokinetics.

![Relationship between A) *C*~max~ for doses of 200 mg and 400 mg ibuprofen in standard acid and fast acting formulations and observed NNT (equation to regression line --0.031 × + 3.1 (*r*^2^ = 0.74)) and B) observed remedication rate (equation to regression line --1.0 × + 74 (*r*^2^ = 0.79)). Calculated using data from ss. Weighted mean *C*~max~ values were multiplied by dose to obtain *C*~max~ values; NNT and percentage remedicating values were taken from tables or text](bcp0080-0381-f5){#fig05}

The advice to take aspirin and NSAIDs with food stems from a desire to protect people from gastrointestinal adverse events; common events like dyspepsia, and rare, serious events like gastrointestinal bleeding. Aspirin is associated with increased rates of adverse events and gastric irritation \[[@b54]\], but there is no evidence that taking occasional doses of NSAIDs or most other analgesics produces higher adverse event rates than placebo \[[@b5]\]. Nor is there any convincing evidence that food prevents any other adverse events \[[@b6]\].

Conclusion
==========

This leaves us with a conundrum. Current advice to take aspirin and NSAIDs with food is of no known benefit, but has a major effect on the most commonly used analgesics, including paracetamol, in a way that probably reduces analgesic efficacy for a given dose and increases the likelihood of additional doses or different analgesics being taken. There is a clear link between higher dose and greater risk of harm for NSAIDs in chronic pain \[[@b55]\]. Analgesics are taken to reduce pain. The evidence we have is strongly suggestive that taking them with food reduces their efficacy, especially those available to the public without prescription. It may be time to rethink research priorities and advice to patients and public.
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